Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by ...

Over time, biosimilars are gaining traction in the US and becoming preferred products, explained James D. Chambers, PhD, of ...

Alvotech's biosimilars aim to lower healthcare costs amid rising drug prices and regulatory pressure against price hikes.

The European Medicines Agency (EMA) could table proposals next year to relax requirements around the need for comparative ...

Joshua Cohen is a Boston-based writer who covers health policy. Biosimilars offer clinically effective treatment alternatives to branded reference drugs at a lower cost. These products are making ...

Part 2 of this series for Global Biosimilars Week dives into the complexities of payer and pharmacy benefit manager (PBM) ...

pharmaphorum interviews Dr Conrad Savoy on the challenges involved with getting biosimilars and biobetters to market, and also the opportunities they present. Biosimilars and biobetters present a ...

Shreehas Tambe, MD & CEO, Biocon Biologics talks about refinancing, upcoming launches, and future roadmap, in a virtual ...

Global Biosimilars Week discussed issues in biosimilar adoption and called for reforms to streamline processes, foster ...

“Biosimilars are clearly a new and big issue for us,” she said, introducing Westminster Health Form’s Biosimilars in the NHS – Commissioning, Development and Engagement with Clinicians and ...

South Korean biosimilar giant Celltrion announced Friday that its biosimilars, Stoboclo and Osenvelt, have been approved by the Ministry of Food and Drug Safety. The two biosimilars, referencing Amgen ...